<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">94087</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Individual'noe dozirovanie‌‌ ingibitorov fosfodiesterazy 5-go tipa kak put' povysheniya effektivnostii bezopasnosti medikamentoznogo lecheniya erektil'noy disfunktsii</article-title><trans-title-group xml:lang="ru"><trans-title>Индивидуальное дозирование‌‌ ингибиторов фосфодиэстеразы 5-го типа как путь повышения эффективностии безопасности медикаментозного лечения эректильной дисфункции</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pchelintsev</surname><given-names>M. V</given-names></name><name xml:lang="ru"><surname>Пчелинцев</surname><given-names>М. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2014</year></pub-date><volume>16</volume><issue>7</issue><issue-title xml:lang="en">VOL 16, NO7 (2014)</issue-title><issue-title xml:lang="ru">ТОМ 16, №7 (2014)</issue-title><fpage>11</fpage><lpage>16</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/94087">https://consilium.orscience.ru/2075-1753/article/view/94087</self-uri><abstract xml:lang="ru"><p>На сегодняшний день эректильная дисфункция (ЭД) является весьма распространенной патологией В настоящее время общепризнан факт, что оптимальным способом лечения ЭД является назначение пациентам препаратов из группы ингибиторов ФДЭ-5 (ИФДЭ-5). Этот класс препаратов отличают высокая эффективность, достигающая 80% и более, хорошая переносимость, удобство применения. Все представители группы ИФДЭ-5 имеют одинаковый механизм действия. Проведено большое количество клинических исследований, в ходе которых были изучены эффективность и безопасность ИФДЭ. Важным фактором, который может вызвать необходимость изменения дозы ИФДЭ-5, является негативное влияние ряда лекарственных препаратов на эректильную функцию, а также лекарственные взаимодействия ИФДЭ-5 с группами лекарств, принимаемых пациентом по тем или иным показаниям. В этом контексте врачом при выборе дозы ИФДЭ-5 должны приниматься во внимание и оцениваться 2 основных вида взаимодействия между лекарствами: фармакодинамическое и фармакокинетическое. Индивидуальный подход к дозированию ИФДЭ-5 повышает эффективность, безопасность и переносимость их применения при лечении пациентов с ЭД.</p></abstract><kwd-group xml:lang="ru"><kwd>эректильная дисфункция</kwd><kwd>лечение</kwd><kwd>ингибиторы ФДЭ-5</kwd><kwd>дозирование</kwd><kwd>взаимодействие</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Бакшеев В.И., Коломоец Н.М., Гончарук А.И. Синдром эректильной дисфункции в практике терапевта. Клин. медицина. 2005; 3: 16-23.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Верткин А.Л. Эректильная дисфункция в практике врача - кардиолога. РМЖ. 2003; 19: 1107-13.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Верткин А.Л., Лоран О.Б., Тополянский А.В. и др. Эректильная дисфункция у кардиологических и терапевтических пациентов. РМЖ. 2001; 25: 1308-17.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Рафальский В.В., Багликов А.Н. Подходы к рациональному выбору ингибиторов фосфодиэстеразы 5-го типа у пациентов с сердечно - сосудистыми заболеваниями. Проблемы эндокринологии. 2010; 6: 63-72.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Balon R, Yeragani V.K, Pohl R, Ramesh C. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993; 54: 209-12.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Billups K.L, Edina M.N, Kaiser D et al. Erectile dysfunction as an early indicator of systemic oxidative stress and endothelial cell dysfunction. J Urol 2003; 169: 323.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Carson C.C, Rajfer J, Eardley I et al. The efficacy and safety of tadalafil: an update. Br J Urol Int 2004: 93: 1276-81.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ferrario C.M, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens 2002; 4 (6): 424-32.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Fink H.A, Mac Donald R, Rutks I.R et al. Sildenafil for male erectile dysfunction: a systematic review and meta - analysis. Arch Intern Med 2002: 162: 1349-60.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 2002; 4 (3): 202-10.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Fogari R, Corradi I, Poletti L et al. Sexual activity in hypertensive males treated with valsartan or carvedilol. A cross - over study. J Hypertens 1999; 17 (Suppl. 3): S65.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Guay A.T. Erectile dysfunction - are you prepared to discuss it? Postgrad Med 1995; 97: 127-43.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Herrmann H.C, Chang G, Klugherz B.D, Mahoney P.D. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Jackson G. Simvastatin and impotence [letter]. BMJ 1997; p. 315-31.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>James C.W, Wu T.S, Mc Nelis K.C. Sexual Dysfunction Secondary to Gemfibrozil. Pharmacotherapy 2002; 22 (2): 123-5.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Johannes C.B, Araujo A.B, Feldman H.A et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. Urol 2000; 163: 460-3.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Khan M.A, Thompson C.S, Sullivan M.E et al. The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 169-74.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Khan M.A, Calvert R.C, Sullivan M.E et al. Normal and pathological erectile function: the potential clinical role of endothelin-1 antagonists. Curr Drug Targets 2000; 1: 247-260.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Khan M.A, Morgan R.J, Mikhailidis D.P. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin 2002; 18 (2): 103-7.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kleinman K.P, Feldman H.A, Johannes C.B et al. A new surrogate variable for erectile dysfunction status in the Massachusetts Male Aging Study. J Clin Epidemiol 2000; 53: 71-8.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kloner R.A. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86: 57F.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Kloner R.A, Mitchell M.I, Bedding A, Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J Urol 2002; 167 (4): 176-7.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ko D.T, Hebert P.R, Coffey C.S et al. Beta - blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288 (3): 351-7.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Llisterri J.L, Lozano Vidal J.V, Aznar Vicente J et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321 (5): 336-41.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Markou S, Perimenis P, Gyftopoulos K et al. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta - analysis of clinical trial reports. Int J Impot Res 2004; 16 (6): 470-8.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Mickley H. Incidence and treatment of sexual dysfunction in heart disease. Ugeskr Laeger 2002; 164 (41): 4760-4.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Nicolosi A, Laumann E.O, Glasser D.B et al. Global Study of Sexual Attitudes and Behaviors Investigators’ Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. J Urol 2004; 64: 991-7.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>NIH Consensus Conference on Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>O’Keefe M, Hunt D.K. Assessment and treatment of impotence. Med Clin North Am 1995; 79: 415-34.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Olsson A.M, Speakman M.J, Dinsmore W.W et al. Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract 2000; 54 (9): 561-6.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Prisant L.M. Fixed low - dose combination in first - line treatment of hypertension. J Hypertens 2002; 20 (Suppl. 1): S11-9.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Ralph D, Mc Nicholas T. UK management guidelines for erectile dysfunction. BMJ 2000; 321 (19): 499-503.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Slag M.F, Morley J.E, Elson M.K et al. Impotence in medical clinic outpatients. JAMA 1983; 249: 1736-40.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Solomon H, Han J.W, Jackson G. Erectile dysfunction and the cardiovascular patients: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-3.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Stewart C, Hogan S. Evidence based review of medicines for sexual dysfunction in men: A report commissioned by the New Zealand Accident Compensation Corporation (ACC). NZHTA Report 2004; 7 (4).</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Webb D.J, Muirhead G.J, Wulff M et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angin. J Am Coll Cardiol 2000; 36: 25.</mixed-citation></ref></ref-list></back></article>
